Novel GLP‐1/GIP mimetics have shown neuroprotective effects in animal models of neurodegenerative disease and may warrant testing in next generation clinical trials (Holscher, 2018; Zhang et al., 2020). Here, GCG is linked to neurodegenerative disease.